Biologic therapies and pregnancy: the story so far
Open Access
- 17 December 2013
- journal article
- research article
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 53 (8) , 1377-1385
Abstract
Biologic therapies have revolutionized treatment outcomes for patients with inflammatory arthritis. However, there remains a concern regarding their safety during conception, pregnancy and breastfeeding. Data on the safety of these treatments are largely limited to uncontrolled case reports. Collective evidence from many hundreds of pregnancies in inflammatory arthritis and IBD have suggested that exposure to anti-TNF therapies at the time of conception or during the first trimester does not result in an increased risk of adverse pregnancy and fetal outcomes. Monoclonal antibodies, and to a lesser extent recombinant fusion proteins, do cross the placenta during the second and third trimester and are functional in the fetus, as evidence by lymphopaenia reported at birth in children exposed to rituximab in utero. In addition, live vaccines should be avoided in children with in utero exposure to biologics for at least the first 6 months of life. The longer-term effects of in utero exposure remain unknown. Studies suggest that many of these drugs do enter breast milk in small amounts, but the extent to which they are absorbed by the infant is less clear. Limited reports have not suggested adverse pregnancy outcomes in women whose partners were exposed to anti-TNF therapies or rituximab at the time of conception. Data on other biologic therapies, including anakinra, abatacept and tocilizumab, in both men and women remain extremely limited.Keywords
This publication has 56 references indexed in Scilit:
- Maternal immunization as a strategy to decrease susceptibility to infection in newborn infantsCurrent Opinion in Infectious Diseases, 2013
- Influence of anti-TNF patient warning regarding avoidance of high risk foods on rates of listeria and salmonella infections in the UKAnnals of the Rheumatic Diseases, 2013
- Placental Transfer of Anti–Tumor Necrosis Factor Agents in Pregnant Patients With Inflammatory Bowel DiseaseClinical Gastroenterology and Hepatology, 2013
- Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient?Annals of the Rheumatic Diseases, 2011
- IgG Placental Transfer in Healthy and Pathological PregnanciesJournal of Immunology Research, 2011
- The Use of Surrogate Antibodies to Evaluate the Developmental and Reproductive Toxicity Potential of an Anti-TNFα PEGylated Fab′ Monoclonal AntibodyToxicological Sciences, 2011
- Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderlyRheumatology, 2010
- ListeriosisSeminars in Fetal and Neonatal Medicine, 2009
- Rates of serious infection, including site‐specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti–tumor necrosis factor therapy: Results from the British Society for Rheumatology Biologics RegisterArthritis & Rheumatism, 2006
- Placental transport of immunoglobulin GVaccine, 2003